Shah P, et al. - Researchers sought to assess the effect of adjunctive ketamine continuous infusion on symptom control and lorazepam infusion requirements for Benzodiazepine (BZD)-resistant alcohol withdrawal patients in the Intensive Care Unit. They performed a retrospective review of patients receiving ketamine adjunctively with a lorazepam infusion for severe alcohol withdrawal between August 2012 and August 2014. Findings suggest that for BZD-refractory patients, adjunctive ketamine could provide symptom control and may potentially reduce lorazepam infusion requirements. It seems that the mechanism of action via the NMDA receptor with ketamine could be beneficial for BZD-resistant alcohol withdrawal.